开云app官网登录入口网页版-官方正版

#标准化疗#

19篇内容 | 946人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1758913, encodeId=d2241e58913ba, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=结果令人鼓舞，肿瘤电场治疗联合标准化疗作为胃癌一线治疗的2期临床研究EF-31达到主要终点, objectType=article, longId=728899, objectId=ab8ce28899e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab8ce28899e0, replyNumber=0, likeNumber=80, createdTime=2022-10-14, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab8ce28899e0, moduleTitle=结果令人鼓舞，肿瘤电场治疗联合标准化疗作为胃癌一线治疗的2期临床研究EF-31达到主要终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ab8ce28899e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758912, encodeId=bdbc1e589125d, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性, objectType=article, longId=724175, objectId=74d6e2417552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d6e2417552, replyNumber=0, likeNumber=73, createdTime=2022-07-31, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d6e2417552, moduleTitle=J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=74d6e2417552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758914, encodeId=15941e5891488, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌, objectType=article, longId=729496, objectId=5ebee29496b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ebee29496b6, replyNumber=0, likeNumber=66, createdTime=2022-07-23, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ebee29496b6, moduleTitle=NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5ebee29496b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758911, encodeId=8f6b1e589112f, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=Blood：标准化疗联合吉妥珠单抗治疗AML, objectType=article, longId=185544, objectId=a879185544c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a879185544c4, replyNumber=0, likeNumber=77, createdTime=2020-11-30, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a879185544c4, moduleTitle=Blood：标准化疗联合吉妥珠单抗治疗AML, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a879185544c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758910, encodeId=0e811e5891098, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=聚合物胶束紫杉醇在晚期非小细胞肺癌治疗中获突破，或将成为标准化疗方案, objectType=article, longId=179380, objectId=18031e9380de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18031e9380de, replyNumber=0, likeNumber=64, createdTime=2020-02-06, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18031e9380de, moduleTitle=聚合物胶束紫杉醇在晚期非小细胞肺癌治疗中获突破，或将成为标准化疗方案, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=18031e9380de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758909, encodeId=96eb1e5890974, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=Lancet oncol：标准化疗方案IVA联合强化阿霉素治疗横纹肌肉瘤的效果和安全性！, objectType=article, longId=141416, objectId=fdd9141416ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdd9141416ba, replyNumber=0, likeNumber=83, createdTime=2018-10-17, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdd9141416ba, moduleTitle=Lancet oncol：标准化疗方案IVA联合强化阿霉素治疗横纹肌肉瘤的效果和安全性！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fdd9141416ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758908, encodeId=8a6a1e58908c6, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响, objectType=article, longId=131089, objectId=56eb131089ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56eb131089ae, replyNumber=0, likeNumber=73, createdTime=2018-09-06, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56eb131089ae, moduleTitle=Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=56eb131089ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758907, encodeId=8d7d1e58907f8, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=NEJM：Nivolumab一线应用对生存的改善不优于标准化疗（CheckMate 026研究）, objectType=article, longId=103122, objectId=540b10312245, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=540b10312245, replyNumber=0, likeNumber=71, createdTime=2017-07-28, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=540b10312245, moduleTitle=NEJM：Nivolumab一线应用对生存的改善不优于标准化疗（CheckMate 026研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=540b10312245)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758904, encodeId=9e921e5890493, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=J Clin Oncol：贝伐珠单抗联合标准化疗用于广泛期SCLC一线治疗的疗效如何？, objectType=article, longId=97609, objectId=1d9b9e609be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d9b9e609be, replyNumber=0, likeNumber=74, createdTime=2017-07-04, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d9b9e609be, moduleTitle=J Clin Oncol：贝伐珠单抗联合标准化疗用于广泛期SCLC一线治疗的疗效如何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1d9b9e609be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758906, encodeId=0e101e58906dc, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=J CLIN ONCOL：塞来考昔联合标准化疗对环氧合酶-2过表达的晚期非小细胞肺癌的III期试验, objectType=article, longId=102867, objectId=c30f10286e18, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c30f10286e18, replyNumber=0, likeNumber=84, createdTime=2017-12-09, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c30f10286e18, moduleTitle=J CLIN ONCOL：塞来考昔联合标准化疗对环氧合酶-2过表达的晚期非小细胞肺癌的III期试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c30f10286e18)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758905, encodeId=57591e58905b1, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=Blood：新型白血病治疗方法优于标准化疗法, objectType=article, longId=101236, objectId=43c41012361f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43c41012361f, replyNumber=0, likeNumber=61, createdTime=2018-04-21, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43c41012361f, moduleTitle=Blood：新型白血病治疗方法优于标准化疗法, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=43c41012361f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758903, encodeId=a3551e589032f, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, objectType=article, longId=43695, objectId=811c4369574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=811c4369574, replyNumber=0, likeNumber=89, createdTime=2015-01-02, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=811c4369574, moduleTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=811c4369574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758901, encodeId=58391e5890105, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=ASCO 2014：克唑替尼一线治疗经选择的NSCLC的PFS显著优于标准化疗, objectType=article, longId=35661, objectId=56fa35661a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56fa35661a4, replyNumber=0, likeNumber=59, createdTime=2014-10-19, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56fa35661a4, moduleTitle=ASCO 2014：克唑替尼一线治疗经选择的NSCLC的PFS显著优于标准化疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=56fa35661a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758899, encodeId=79ad1e5889937, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=ASCO 2014：贝伐单抗标准化疗用于SCLC疗效欠佳, objectType=article, longId=35084, objectId=0a903508402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a903508402, replyNumber=0, likeNumber=71, createdTime=2014-12-02, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a903508402, moduleTitle=ASCO 2014：贝伐单抗标准化疗用于SCLC疗效欠佳, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0a903508402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758902, encodeId=12ca1e589025d, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=ASCO 2014：乳腺癌戈舍瑞林+标准化疗保留生育力（S0230/POEMS研究）, objectType=article, longId=35737, objectId=335135e37ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=335135e37ca, replyNumber=0, likeNumber=72, createdTime=2014-10-03, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=335135e37ca, moduleTitle=ASCO 2014：乳腺癌戈舍瑞林+标准化疗保留生育力（S0230/POEMS研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=335135e37ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758900, encodeId=8abd1e58900f1, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=ASCO 2014：低剂量环磷酰胺加标准化疗有益于乳腺癌, objectType=article, longId=35121, objectId=209935121d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=209935121d4, replyNumber=0, likeNumber=66, createdTime=2015-04-08, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=209935121d4, moduleTitle=ASCO 2014：低剂量环磷酰胺加标准化疗有益于乳腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=209935121d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758896, encodeId=5ca21e5889654, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=NEJM：克唑替尼治疗ALK阳性的晚期肺癌疗效优于标准化疗, objectType=article, longId=19948, objectId=7ed71994855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ed71994855, replyNumber=0, likeNumber=84, createdTime=2014-05-03, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ed71994855, moduleTitle=NEJM：克唑替尼治疗ALK阳性的晚期肺癌疗效优于标准化疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7ed71994855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758898, encodeId=96971e58898b2, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=JCO：标准化疗可改善部分复发或难治性PTCL患者结局, objectType=article, longId=28300, objectId=1eaf283001a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1eaf283001a, replyNumber=0, likeNumber=59, createdTime=2014-10-12, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1eaf283001a, moduleTitle=JCO：标准化疗可改善部分复发或难治性PTCL患者结局, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1eaf283001a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1758897, encodeId=f4b81e5889706, content=<a href='/topic/show?id=a79661923b4' target=_blank style='color:#2F92EE;'>#标准化疗#</a>, objectTitle=Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）, objectType=article, longId=26016, objectId=35c626016f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c626016f7, replyNumber=0, likeNumber=57, createdTime=2013-12-30, rootId=0, userName=124987a0m78(暂无昵称), userId=aa7737388244, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c626016f7, moduleTitle=Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=35c626016f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

标准化疗

2020-05-29

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

结果令人鼓舞，肿瘤电场治疗联合标准化疗作为胃癌一线治疗的2期临床研究EF-31达到主要终点

2022-10-14

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性

2022-07-31

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

NEJM Evid：durvalumab联合标准化疗治疗局部晚期或转移性胆道癌

2022-07-23

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

Blood：标准化疗联合吉妥珠单抗治疗AML

2020-11-30

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

聚合物胶束紫杉醇在晚期非小细胞肺癌治疗中获突破，或将成为标准化疗方案

2020-02-06

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

Lancet oncol：标准化疗方案IVA联合强化阿霉素治疗横纹肌肉瘤的效果和安全性！

2018-10-17

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响

2018-09-06

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

NEJM：Nivolumab一线应用对生存的改善不优于标准化疗（CheckMate 026研究）

2017-07-28

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

J Clin Oncol：贝伐珠单抗联合标准化疗用于广泛期SCLC一线治疗的疗效如何？

2017-07-04

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

J CLIN ONCOL：塞来考昔联合标准化疗对环氧合酶-2过表达的晚期非小细胞肺癌的III期试验

2017-12-09

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

Blood：新型白血病治疗方法优于标准化疗法

2018-04-21

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者

2015-01-02

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

ASCO 2014：克唑替尼一线治疗经选择的NSCLC的PFS显著优于标准化疗

2014-10-19

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

ASCO 2014：贝伐单抗标准化疗用于SCLC疗效欠佳

2014-12-02

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

ASCO 2014：乳腺癌戈舍瑞林+标准化疗保留生育力（S0230/POEMS研究）

2014-10-03

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

ASCO 2014：低剂量环磷酰胺加标准化疗有益于乳腺癌

2015-04-08

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

NEJM：克唑替尼治疗ALK阳性的晚期肺癌疗效优于标准化疗

2014-05-03

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

JCO：标准化疗可改善部分复发或难治性PTCL患者结局

2014-10-12

124987a0m78(暂无昵称) (审核中...)

前往app查看评论内容

#标准化疗#

Lancet Oncol：EGFR野生型NSCLC二线治疗：厄洛替尼不敌标准化疗（TAILOR研究）

2013-12-30

科室
- - 订阅+
  - 更多科室
工具
服务